A detailed history of Rafferty Asset Management, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 203,834 shares of BMRN stock, worth $13.6 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
203,834
Previous 226,635 10.06%
Holding current value
$13.6 Million
Previous $18.7 Million 23.21%
% of portfolio
0.05%
Previous 0.07%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$69.02 - $93.84 $1.57 Million - $2.14 Million
-22,801 Reduced 10.06%
203,834 $14.3 Million
Q2 2024

Aug 13, 2024

BUY
$74.43 - $92.22 $8.93 Million - $11.1 Million
119,938 Added 112.41%
226,635 $18.7 Million
Q1 2024

May 13, 2024

BUY
$83.81 - $99.0 $846,313 - $999,702
10,098 Added 10.45%
106,697 $9.32 Million
Q4 2023

Feb 13, 2024

SELL
$76.22 - $98.51 $162,043 - $209,432
-2,126 Reduced 2.15%
96,599 $9.31 Million
Q3 2023

Nov 13, 2023

BUY
$85.07 - $94.48 $667,884 - $741,762
7,851 Added 8.64%
98,725 $8.74 Million
Q2 2023

Aug 11, 2023

BUY
$86.68 - $100.3 $1.35 Million - $1.57 Million
15,624 Added 20.76%
90,874 $7.88 Million
Q1 2023

May 11, 2023

SELL
$87.74 - $117.27 $307,002 - $410,327
-3,499 Reduced 4.44%
75,250 $7.32 Million
Q4 2022

Feb 13, 2023

BUY
$80.93 - $108.63 $333,917 - $448,207
4,126 Added 5.53%
78,749 $8.15 Million
Q3 2022

Nov 14, 2022

BUY
$82.16 - $96.94 $1.96 Million - $2.31 Million
23,802 Added 46.83%
74,623 $6.33 Million
Q2 2022

Aug 12, 2022

SELL
$71.48 - $86.85 $1.4 Million - $1.7 Million
-19,562 Reduced 27.79%
50,821 $4.21 Million
Q1 2022

May 13, 2022

BUY
$74.28 - $92.69 $613,998 - $766,175
8,266 Added 13.31%
70,383 $5.43 Million
Q4 2021

Feb 10, 2022

BUY
$71.72 - $91.47 $1.59 Million - $2.03 Million
22,161 Added 55.46%
62,117 $5.49 Million
Q3 2021

Nov 10, 2021

BUY
$74.77 - $85.47 $611,095 - $698,546
8,173 Added 25.72%
39,956 $3.09 Million
Q2 2021

Aug 10, 2021

SELL
$75.51 - $84.79 $877,275 - $985,090
-11,618 Reduced 26.77%
31,783 $2.65 Million
Q1 2021

May 10, 2021

BUY
$74.73 - $90.69 $2.37 Million - $2.87 Million
31,673 Added 270.06%
43,401 $3.28 Million
Q4 2020

Feb 10, 2021

SELL
$72.61 - $90.2 $3.69 Million - $4.58 Million
-50,828 Reduced 81.25%
11,728 $1.03 Million
Q3 2020

Nov 13, 2020

BUY
$71.87 - $131.03 $2.21 Million - $4.02 Million
30,708 Added 96.42%
62,556 $4.76 Million
Q2 2020

Aug 07, 2020

SELL
$79.55 - $124.22 $189,488 - $295,892
-2,382 Reduced 6.96%
31,848 $3.93 Million
Q1 2020

May 15, 2020

SELL
$71.37 - $96.85 $3.09 Million - $4.19 Million
-43,235 Reduced 55.81%
34,230 $2.89 Million
Q4 2019

Feb 10, 2020

SELL
$64.27 - $86.37 $2.6 Million - $3.49 Million
-40,435 Reduced 34.3%
77,465 $6.55 Million
Q3 2019

Nov 14, 2019

BUY
$67.4 - $85.11 $2.08 Million - $2.62 Million
30,825 Added 35.4%
117,900 $7.95 Million
Q2 2019

Aug 09, 2019

BUY
$80.35 - $93.9 $825,114 - $964,259
10,269 Added 13.37%
87,075 $7.46 Million
Q1 2019

May 15, 2019

BUY
$84.2 - $98.62 $4.9 Million - $5.74 Million
58,252 Added 313.96%
76,806 $6.82 Million
Q4 2018

Feb 11, 2019

SELL
$80.14 - $106.07 $141,447 - $187,213
-1,765 Reduced 8.69%
18,554 $1.58 Million
Q3 2018

Nov 09, 2018

BUY
$93.92 - $105.72 $268,423 - $302,147
2,858 Added 16.37%
20,319 $1.97 Million
Q2 2018

Aug 14, 2018

SELL
$76.01 - $99.03 $138,870 - $180,927
-1,827 Reduced 9.47%
17,461 $1.65 Million
Q1 2018

May 15, 2018

BUY
$77.67 - $92.63 $268,427 - $320,129
3,456 Added 21.83%
19,288 $1.56 Million
Q4 2017

Feb 14, 2018

SELL
$80.76 - $95.13 $95,296 - $112,253
-1,180 Reduced 6.94%
15,832 $1.41 Million
Q3 2017

Nov 13, 2017

BUY
$80.6 - $94.95 $1.37 Million - $1.62 Million
17,012
17,012 $1.58 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.